SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron's upcoming earnings are a hot topic, with anticipation building around whether they can justify the stock's recent surge driven by AI data center growth and rising memory prices. Community sentiment is mixed, as some believe strong guidance is needed to avoid a sell-off, while others are betting on a continued rally reminiscent of Oracle's recent performance. The focus is on Micron's ability to capitalize on the AI boom and sustain its growth trajectory in the competitive semiconductor landscape.

Bollinger Innovations Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.

Bollinger Innovations Inc.

Bollinger Innovations Inc

BINI is trending due to a recent reverse stock split, sparking heated debates about the company's future and potential for further dilutions. Community members are discussing the possibility of short squeezes versus the likelihood of continued decline, with many expressing strong distrust of the company's management. The stock's history of reverse splits and its impact on share value are also prominent points of discussion.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending as investors discuss its recent price action and potential catalysts, including an upcoming hardware event. Community sentiment is mixed, with some expressing frustration over the stock's performance compared to its tech peers, while others see it as a buying opportunity amid broader market concerns and an FTC trial.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto token CAW.X, also known as crow with knife, is trending due to its active and vocal community. Discussions revolve around its multi-chain functionality and deflationary mechanisms. The community is also speculating about potential connections to Coinbase and other listings.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to increased investor attention surrounding its potential role in next-generation AI hardware, particularly after a recent presentation at CIOE 2025 showcasing its optical engines. Community discussions highlight the company's strategic partnerships and anticipation for purchase order news. Investors are closely monitoring developments, expecting POET to capitalize on the growing demand for efficient, high-speed data transfer solutions in the AI sector.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members point to bullish chart patterns and strong accumulation signals, anticipating a potential breakout. Discussions highlight consistent buying pressure and increasing demand, suggesting a positive shift in market sentiment for the crypto. Some users are skeptical of the coin, as well.

Super League Enterprise, Inc. creates innovative and immersive entertainment experiences, platform and audience monetization and dynamic content feeding channels across the world’s top gaming platforms. Fueled by an insatiable desire to stay on the forefront of this ever-evolving meta landscape, Super League pioneer's proprietary digital solutions provide unparalleled access to the global gaming audience. It also creates vibrant in-game communities through the development of innovative experiences and custom content, delivering powerful opportunities for brands and advertisers to achieve impactful insights, and marketing outcomes with audiences of all ages. The company was founded by John C. Miller, David Steigelfest, and Brett Morris on October 1, 2014 and is headquartered in Santa Monica, CA.

Super League Enterprise Inc

Fueled by news of a strategic investment from Evo Fund and plans for a digital asset treasury, Super League Enterprise is trending with traders citing its low float and potential for a significant squeeze. The community is actively discussing entry and exit strategies, with some eyeing a multi-day run while others caution against a potential pump and dump. This micro-float stock may continue to see volatility as traders assess its long-term value.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending amidst discussions about a potential AI content deal with Google and OpenAI, with the community speculating on the impact of such partnerships. Some investors are bullish, citing revenue growth and potential for further monetization, while others express concern over the platform's content moderation and potential for political bias. Overall, the stock's volatility and potential for significant growth are key discussion points.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance Holding Co. ($BETR) is trending due to a recent endorsement from a prominent investor who compared it to the "Shopify of mortgages," fueling speculation of massive growth potential. The community is actively discussing the possibility of a short squeeze, potential price targets, and comparing it to other meme stocks like $OPEN and $RKT. Some are speculating about potential partnerships and expressing concerns about volatility and possible dilution.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to increasing community excitement around potential hyperscaler deals and its close ties to Nvidia's AI initiatives. Bullish sentiment is fueled by the anticipation of a short squeeze, with many traders suggesting that APLD's unique position in AI data centers could drive significant gains. The stock's recent performance and potential for future growth are sparking discussions about long-term investment and potential price targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem (VSTM) Upgraded to Buy: Here's What You Should Know

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +54.12% and -86.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?  

Shares of Verastem Oncology (VSTM) dropped 19% on Monday despite the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-updated-data-partner-genfleet">announcing</a> positive updated data from the dose escalation phase of its trial for cancer therapy GFH375, conducted by its partner, GenFleet Therapeutics.In a study in China, GFH375, also known as VS-7375 in the U.S., demonstrated an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and a response rate of 42% in those with non-small cell lung cancer, the company stated.Verastem stated that data from its partner supports the advancement of its clinical program for VS-7375 in the U.S., which is slated to start in mid-2025.The company is activating sites in the U.S. for VS-7375 to begin enrollment in the trial. The study has the potential to expand globally and will evaluate the safety and efficacy of VS-7375 in patients with advanced, KRAS G12D-mutant solid tumors.The KRAS G12D mutation, a genetic alteration in the KRAS gene, is common in various cancers, particularly pancreatic cancer, colorectal cancer, and lung adenocarcinoma.As part of the collaboration between Verastem and GenFleet, Verastem has development and commercialization rights for the cancer therapy outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan.On Stocktwits, retail sentiment around Verastem rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_12_42_50_PM_png_7c68caaf50.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock could be tanking owing to the Chinese partnership.<stembedurl>https://stocktwits.com/Universaal/message/616509493</stembedurl>According to data from Koyfin, all of the nine analysts covering the stock rate it ‘Buy’ or higher. The stock has an average price target of $15.75, representing an upside of over 150%.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> is down by 6% this year but up by about 55% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-s-push-toward-fully-automated-ads-to-reportedly-debut-by-year-end/chkY2oMRbHJ">Meta’s Push Toward Fully Automated Ads To Reportedly Debut By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.

Equity

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

The U.S. Food and Drug Administration on Thursday granted accelerated approval to Verastem Oncology’s (VSTM) combination therapy for adult patients with a particular type of ovarian cancer.The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low">treat</a> patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.LGSOC is a rare ovarian cancer which is highly recurrent and less sensitive to chemotherapy compared to high-grade serous ovarian cancer. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease, as per Verastem.Avmapki Fakzynja Co-pack is the first and only FDA-approved medicine for this disease, Verastem said, while adding that the oral medicine pack is expected to be available for adult patients in the U.S. in one week.The FDA previously granted priority review to Verastem’s drug application and also designated it a breakthrough therapy and orphan drug.Late last month, the company announced a $75 million private placement. The proceeds would be used to fund the launch of the combination therapy, among other things. &nbsp;On Stocktwits, retail sentiment around Verastem rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_08_at_1_01_06_PM_png_213d5d0710.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits</figcaption></figure>The stock is trading 3% higher on Thursday afternoon after a trading halt.&nbsp;<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained by about 6% this year but has fallen by about 39% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/viatris-reports-q1-earnings-above-estimates/chifqcaRbk1">Viatris Q1 Earnings Exceed Wall Street Expectations, Company Raises Full-Year Profit Outlook: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster...

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.62	--	--	N/A
Q2 '25	-$0.73	-$0.39	46.41%	BEAT
Q1 '25	-$0.70	-$0.96	-37.14%	MISSED
Q4 '24	-$0.83	-$1.33	-60.48%	MISSED
Q3 '24	-$0.74	-$0.60	18.67%	BEAT

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest VSTM News

VSTM Verastem Inc